NASDAQ:CLSD • US1850632035
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CLEARSIDE BIOMEDICAL INC (CLSD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-18 | Needham | Reiterate | Hold -> Hold |
| 2025-07-18 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-07-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-07-17 | Needham | Downgrade | Buy -> Hold |
| 2025-05-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-15 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-28 | Needham | Maintains | Buy -> Buy |
| 2025-03-06 | Needham | Reiterate | Buy -> Buy |
| 2025-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-10-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-10 | Needham | Maintains | Buy -> Buy |
| 2024-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-21 | Chardan Capital | Initiate | Buy |
| 2024-08-13 | Needham | Reiterate | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-25 | Needham | Reiterate | Buy -> Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.33M -95.50% | 8.226M 518.50% | 1.664M -79.77% | 3.213M 93.09% | -100.00% | 25.096M | 106.76M 325.41% | 185.4M 73.66% | 196.03M 5.73% | 290.39M 48.14% | ||
| EBITDA YoY % growth | -30.13M -6,747.73% | -24.777M 17.77% | -28.656M -15.66% | -17.655M 38.39% | -7.406M 58.05% | -11.005M -48.59% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -30.28M -4,783.87% | -24.844M 17.95% | -28.882M -16.25% | -16.116M 44.20% | -14.28M 11.39% | -14.28M | -12.642M 11.47% | 43.039M 440.43% | 97.057M 125.51% | 158.56M 63.37% | 243.8M 53.76% | |
| Operating Margin | -2,276.69% | -302.02% | -1,735.70% | -501.59% | N/A | N/A | -50.38% | 40.31% | 52.35% | 80.89% | 83.96% | |
| EPS YoY % growth | -8.25 -5,400.00% | -7.95 3.64% | -6.75 15.09% | -2.91 56.93% | -2.60 10.53% | -2.60 | -0.77 70.59% | 13.16 1,820.00% | 17.60 33.72% | 21.73 23.48% | 33.35 53.52% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.61 59.20% | -0.20 87.70% | -0.27 70.08% | -0.30 74.05% | -0.29 52.00% |
| Revenue Q2Q % growth | 204K -33.33% | 102K -95.62% | 9.09M 1,747.56% | 9.136M 4,445.27% | 9.182M 4,400.98% |
| EBITDA Q2Q % growth | -2.01M 70.96% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.57M 50.06% | N/A | N/A | N/A | N/A |
All data in USD
11 analysts have analysed CLSD and the average price target is 61.2 USD. This implies a price increase of 14826.83% is expected in the next year compared to the current price of 0.41.
CLEARSIDE BIOMEDICAL INC (CLSD) will report earnings on 2026-03-25, after the market close.
The consensus EPS estimate for the next earnings of CLEARSIDE BIOMEDICAL INC (CLSD) is -0.61 USD and the consensus revenue estimate is 204.00K USD.
The expected long term growth rate for CLEARSIDE BIOMEDICAL INC (CLSD) is -25.99%.